MicroTransponder, Inc.

S-1 filed

Mobia Medical, Inc. is conducting its initial public offering (IPO) to raise capital through the sale of common stock. The company develops medical devices for chronic stroke recovery, with its Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System being the first FDA-approved solution for ischemic stroke survivors with upper extremity impairments. The IPO aims to accelerate growth, expand market reach, and fund further research and development. The shares are expected to trade on a specified exchange under the symbol 'MOBI' following the offering.

DRS/A amended

Mobia Medical, Inc. is preparing for its initial public offering (IPO) with Amendment No. 2 to its draft registration statement, filed confidentially with the SEC on March 24, 2026. The company aims to raise capital through the sale of common stock, with an expected offering price range and anticipated trading on a specified exchange. The filing highlights the company's proprietary Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System, the first FDA-approved solution for chronic ischemic stroke survivors with upper extremity impairments. The filing emphasizes clinical data demonstrating efficacy in restoring motor function, along with a focus on market growth and regulatory milestones.

DRS/A amended

MicroTransponder, Inc. filed an amended draft registration statement (DRS/A) on March 11, 2026, updating its initial public offering (IPO) details. The filing reflects a name change to Mobia Medical, Inc., with updated corporate information, underwriters, and legal counsel. The amendment remains confidential and has not been publicly filed with the SEC.

DRS filed

MicroTransponder, Inc. is conducting its initial public offering (IPO) to raise capital, with a focus on its FDA-approved Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System for chronic ischemic stroke recovery. The company, an emerging growth company, aims to commercialize its medical device targeting motor impairments in stroke survivors. The IPO involves offering shares of common stock, with underwriters including BofA Securities, J.P. Morgan, and Goldman Sachs & Co. LLC. The filing highlights risks related to regulatory approvals, market competition, and reliance on its proprietary technology.